Dr.Β StevenΒ Rosenberg
MD, PhD
Chief, Surgery Branch, National Cancer Institute
corporate_fareNational Cancer Institute, Bethesda, MD
Steven Rosenberg
MD, PhD
Dr. Steven A. Rosenberg is a surgeon-scientist and Chief of the Surgery Branch at the National Cancer Institute (NCI) in Bethesda, Maryland. He is recognised as a pioneer of cancer immunotherapy, with foundational work in tumour-infiltrating lymphocyte (TIL) therapy and adoptive cell transfer for advanced cancer.
Dr. Rosenberg has led the NCI Surgery Branch since 1974, building an internationally recognised cancer immunotherapy research programme at the NIH Clinical Center. His studies of interleukin-2 led to its US FDA approval for metastatic melanoma and renal cancer, and his cell-transfer immunotherapy work produced durable complete remissions in patients with advanced melanoma. He pioneered gene therapy and was the first to successfully insert foreign genes into humans, and his laboratory contributed to the early clinical development of CAR T-cell therapy for aggressive lymphomas. His more recent work develops personalised T-cell therapies that target unique mutations in a patient's cancer. He has published more than 1,200 peer-reviewed papers and received the 2023 National Medal of Technology and Innovation, the United States' highest honour for technological achievement.
Access to NCI Surgery Branch immunotherapy is through research protocols with protocol-specific eligibility screening. CancerFax can help international patients organise their medical records and prepare a structured case summary for specialist or clinical-trial review, subject to eligibility and the trial team's acceptance.
Why Consider Dr. Steven Rosenberg?
Dr. Rosenberg's work has shaped modern cancer immunotherapy and remains central to advanced cell-therapy research for melanoma and solid tumours.
Areas of Specialization
Cancer immunotherapy and adoptive cell therapy
Adoptive Cell Therapy
Cell-based immunotherapies that use a patient's own immune cells to target cancer.
- arrow_rightCollection and laboratory expansion of tumour-derived T cells
- arrow_rightReinfusion with lymphodepletion and IL-2 support in research protocols
- arrow_rightFoundational approach behind FDA-approved lifileucel for melanoma
- arrow_rightTCR-engineered T cells targeting tumour-specific mutations
- arrow_rightCAR T-cell approaches studied in lymphoma and solid tumours
Immunotherapy for Advanced Cancer
Systemic immune-based treatments for metastatic disease.
- arrow_rightHigh-dose IL-2 for selected metastatic melanoma and renal cancer
- arrow_rightBasis of the FDA-approved IL-2 immunotherapy
- arrow_rightPersonalised T-cell therapy targeting patient-specific cancer mutations
- arrow_rightApplied to selected epithelial solid tumours in research settings
Clinical & Research Services
Investigational immunotherapy and specialist evaluation
Dr. Rosenberg's clinical work is delivered through NCI Surgery Branch research protocols at the NIH Clinical Center. The services below reflect investigational immunotherapy and specialist review rather than routine outpatient care.
Adoptive Cell Therapy Programmes
Medical OncologyAdministration of cell-based immunotherapies within NCI research protocols.
Specialist Immunotherapy Evaluation
Complex DiseaseAssessment of advanced or treatment-refractory cancers for cell-therapy approaches.
Multidisciplinary Trial Review
MultidisciplinaryCoordinated review for clinical-trial-based immunotherapy.
Second Opinion Consultations
Second OpinionIndependent expert review of advanced cancer cases.
Research & Publications
Foundational cancer immunotherapy research
Dr. Rosenberg has authored more than 1,200 peer-reviewed papers. A fuller publication list is available through NIH and PubMed.
Education & Training
Dr. Rosenberg trained at Johns Hopkins and Harvard before completing surgical residency in Boston and joining the National Cancer Institute.
Clinical Experience
Dr. Rosenberg has led the NCI Surgery Branch since 1974, where his laboratory and clinical programme have shaped modern cancer immunotherapy.
Languages & International
Dr. Rosenberg consults in English.
CancerFax can coordinate professional medical interpreter support for international patients.
CancerFax can coordinate professional medical interpreter support when required.
How CancerFax Helps You Access Dr. Steven Rosenberg
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Steven Rosenberg's team β with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history β prepared as a structured clinical summary for Dr. Steven Rosenberg's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Steven Rosenberg before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Steven Rosenberg's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Steven Rosenberg's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Steven Rosenberg's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Steven Rosenberg
Dr. Steven A. Rosenberg is a surgeon-scientist and Chief of the Surgery Branch at the National Cancer Institute (NCI) in Bethesda, Maryland. He is recognised as a pioneer of cancer immunotherapy and is best known for developing tumour-infiltrating lymphocyte (TIL) therapy and adoptive cell transfer.
TIL therapy uses immune cells taken from a patient's own tumour, which are expanded in a laboratory and infused back after preparative treatment. The first FDA-approved TIL therapy (lifileucel) is approved for a specific group of adults with advanced melanoma who have had prior therapy. TIL and related cell therapies for other cancers remain specialised and often investigational, so eligibility must be confirmed by the treating or trial team.
Access to NCI Surgery Branch immunotherapy is through research protocols, which require protocol-specific screening and eligibility confirmation by the trial team. CancerFax can help international patients organise their reports and prepare a structured case summary for review, but acceptance is never guaranteed and is decided by the institution.
Submit your medical reports through CancerFax. Our team reviews the documents, prepares the case, and helps assess whether the cancer type and treatment stage appear relevant for TIL or adoptive cell therapy evaluation, then coordinates next steps with the relevant centre, subject to availability.
His work is most closely associated with metastatic melanoma and advanced solid tumours, including gastrointestinal, breast, and pancreatic cancers, as well as selected lymphomas studied in adoptive cell therapy research.
No. No cancer therapy guarantees a response. Expected benefit, risks, and eligibility vary from patient to patient, and any treatment decision must be made by the qualified treating team after a full review of the medical record.
Connect with Steven Rosenberg Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.